Construction method and application of animal model
Patent Information
- Application Number
- CN202410901032.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-12
Smart Images

Figure SMS_1 
Figure HDA0004930475990000011 
Figure HDA0004930475990000012
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for constructing an animal model and application thereof. Background Art
[0002] Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by repetitive stereotyped behaviors, social interaction and communication disorders, language disorders, etc. ASD patients often show impaired social interaction, language disorders (ranging from language delay to speech loss), repetitive and / or compulsive behaviors and verbal imitation, hyperactivity, memory deficits, abnormal excitement of learning, motor skills or other neurological functions, and hyper- or hyposensitivity to sensory stimulation, anxiety, difficulty adapting to new environments and habits. Therefore, ASD patients bring a huge burden to their families and the entire society. Despite the high prevalence and great harm of ASD, its cause remains unclear.
[0003] A key problem encountered in the ASD research process is the lack of a simple and easily repeatable animal model. Many research institutions are committed to basic experiments on autism and autistic-like behaviors, so there is an urgent need for a stable experimental animal model with a clear mechanism. Summary of the invention
[0004] The purpose of the first aspect of the present invention is to provide a sgRNA.
[0005] The second aspect of the present invention aims to provide a kit.
[0006] The purpose of the third aspect of the present invention is to provide the use of the sgRNA of the first aspect of the present invention or the kit of the second aspect of the present invention in constructing an animal model of MARK2 gene mutation.
[0007] The purpose of the fourth aspect of the present invention is to provide a method for constructing a MARK2 gene mutation animal model based on CRISPR / Cas9 technology.
[0008] The purpose of the fifth aspect of the present invention is to provide an application of the gene mutation animal model constructed by the method described in the fourth aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenesis of autism.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] In a first aspect of the present invention, a sgRNA specifically targeting the MARK2 gene is provided, wherein the sgRNA comprises sgRNA1 and / or sgRNA2, wherein the sequence of the sgRNA1 is 5'-GTGGAGAGGACGCTGTTCT GTGG-3'; and the sequence of the sgRNA2 is 5'-TCTGTTTGTGCTGGTGGAGAGG-3'.
[0011] The second aspect of the present invention provides a kit, which comprises the sgRNA of the first aspect of the present invention.
[0012] In some embodiments of the present invention, the kit further comprises Cas9 mRNA and a homologous vector containing a mutation site, and the mutation site is c.1416delC.
[0013] In some embodiments of the present invention, the nucleotide sequence of the homologous vector containing the mutation site is: 5'-ACTGGACAGCACTGGCTCCTGTGACACAGTACTTGCCCTCTATTTCCCACAGAACAGCGT-CTCTCCACCAGCACAAACAGAAGCAGGAACTCCCCACTTTTGGACAGG GCCAGCCTTGGCC-3'.
[0014] In some embodiments of the present invention, the kit further comprises an amplification primer and / or a sequencing primer.
[0015] In some embodiments of the present invention, the sequence of the amplification primer is:
[0016] Rat MARK2-F: 5'-AAAGTGCCTGCCAGCCCTCT-3';
[0017] Rat MARK2-R: 5'-CAGTTTAGTGAGCTGCTCACTGGTAC-3'.
[0018] In some embodiments of the present invention, the sequence of the sequencing primer is: 5'-AGGGCGGAAAGCCAGCAGCA-3'.
[0019] The third aspect of the present invention provides the use of the sgRNA of the first aspect of the present invention or the kit of the second aspect of the present invention in constructing an animal model of MARK2 gene mutation.
[0020] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.
[0021] In some preferred embodiments of the present invention, the animal model is a rat.
[0022] The fourth aspect of the present invention provides a method for constructing a MARK2 gene mutation animal model based on CRISPR / Cas9 technology, the method comprising constructing the model using the kit of the second aspect of the present invention.
[0023] In some embodiments of the present invention, the method comprises: introducing a mixture of the Cas9 mRNA, the homologous vector containing the mutation site and the sgRNA into the fertilized egg of the model animal, obtaining a viable fertilized egg, transplanting it into a surrogate mother, breeding, obtaining offspring and performing genotype identification and screening.
[0024] In some embodiments of the present invention, in the mixture, the mass ratio of the Cas9 mRNA, the homologous vector containing the mutation site, the sgRNA1, and the sgRNA2 is 1:0.5-1.5:0.5-1.5:0.5-1.5.
[0025] In some embodiments of the present invention, in the mixture, the final concentrations of the Cas9 mRNA, the homologous vector containing the mutation site, the sgRNA1, and the sgRNA2 are all 100 to 300 ng / μL.
[0026] In some embodiments of the present invention, the method of introducing comprises injection.
[0027] In some embodiments of the present invention, the genotype identification and screening includes taking tail blood from offspring animals, amplifying and sequencing by PCR.
[0028] In some preferred embodiments of the present invention, the primers used in the PCR amplification include a primer pair of Rat MARK2-F and Rat MARK2-R, the base sequence of the primer Rat MARK2-F is shown in SEQ ID NO:4, and the base sequence of the primer RatMARK2-R is shown in SEQ ID NO:5.
[0029] In some preferred embodiments of the present invention, the base sequence of the sequencing primer used in the sequencing process is shown in SEQ ID NO:6.
[0030] In some embodiments of the present invention, the viable fertilized eggs are transplanted into a surrogate mother and the offspring obtained by breeding are named F0 generation animal model; the positive F0 generation animal model obtained by genotype identification and screening is mated with the wild type to breed an F1 generation animal model; the F1 generation heterozygous animal model obtained by genotype identification and screening is hybridized to breed an F2 generation animal model, and the positive F2 generation homozygous animal model, i.e., the MARK2 gene mutation animal model, is obtained by genotype identification and screening.
[0031] In some embodiments of the present invention, the animal model is one of a mouse, a rat, and a monkey.
[0032] In some preferred embodiments of the present invention, the animal model is a rat.
[0033] The fifth aspect of the present invention provides the use of the MARK2 gene mutation animal model constructed by the method described in the fourth aspect of the present invention in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.
[0034] The beneficial effects of the present invention are:
[0035] The present invention is the first to find that the MARK2 gene is mutated in the genome of children with autism, and the mutation site is c.1416delC. To this end, based on the mutation site, the present invention provides a sgRNA that specifically targets the MARK2 gene and a kit containing the sgRNA, through which an animal model of MARK2 gene mutation (c.1416delC) can be constructed based on CRISPR / Cas9 gene editing technology; the animal model has higher construction efficiency, controllability, good repeatability, and is easy to breed and raise, which makes up for the shortcomings of existing animal models, and is more stable and more in line with clinical characteristics, which is helpful for the pathogenic mechanism of autism and its application in the development of drugs for the treatment of autism, and provides a good foundation for the pathogenesis and intervention research of autism. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is a schematic diagram of the construction principle of the autism animal model of MARK2 gene mutant rats using CRISPR / Cas9 in the present invention.
[0037] Figure 2 This is the sequencing identification result of F0 generation MARK2 gene mutation heterozygous rats (number #109).
[0038] Figure 3 The expression levels of MARK2 protein in F2 generation wild-type (WT) and MARK2 gene mutation homozygous (KI / KI) rats. Figure 3 A is a western blot image of MARK2 protein expression in wild-type (WT) and MARK2 gene mutation homozygous (KI / KI) rats; Figure 3 B is Figure 3 Statistical graph of MARK2 protein expression in A.
[0039] Figure 4 These are the behavioral test results of wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats in the F2 generation. Figure 4 A shows the results of ultrasonic vocalization detection experiments on wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats. Figure 4 B is the statistical results of the grooming frequency of wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats. Figure 4 C shows the results of the three-box social experiment of wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats. DETAILED DESCRIPTION
[0040] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.
[0041] Unless otherwise specified, the materials and reagents used in this example were obtained from commercial sources.
[0042] Example 1
[0043] In clinical work, the inventor found an autistic child with typical autism symptoms. Further sequencing and analysis of the genomic DNA revealed a mutation in the MARK2 gene, c.1416delC. Both of his parents were heterozygous for the mutation and had no obvious clinical phenotype of autism. Based on the mutation site c.1416delC of the child, the inventor used CRISPR / Cas9 technology to construct a MARK2 mutant gene knock-in rat animal model to test whether it can be used as an autism model. The method for constructing the animal model includes the following steps:
[0044] (1) Cas9 / gRNA target design
[0045] The nucleotide sequence of the rat MARK2 gene (NM_021699.1) was downloaded from the NCBI database, and homology comparison was performed. According to the mutation site c.1416delC of the child, the mutation site c.1416delC was determined on the homologous sequence of the rat. According to this site sequence, sgRNA sequences were designed, including sgRNA1 and sgRNA2, wherein the nucleotide sequence of sgRNA1 is 5'-GTGGAGAGGACGCTGTTCTGTGG-3' (SEQ ID NO: 1), and the nucleotide sequence of sgRNA2 is 5'-TCTGTTTGTGCTGGTGGAGAGG-3' (SEQ ID NO: 2) ( Figure 1 ).
[0046] (2) Construction of homologous recombination vector (Donor vector)
[0047] The homologous recombination vector Donor vector carries a mutation site, and its vector sequence is 5'-ACTGGACAGCACTGGCTCCTGTGACACAGTACTTGCCCTCTATTTCCCACAGAA CAGCGTCTCTCCACCAGCACAAACAGAAGCAGGAACTCCCCACTTTTGGACAGGG CCAGCCTTGGCC-3' (SEQ ID NO: 3)
[0048] (3) sgRNA in vitro transcription: sgRNA1 and sgRNA2 were designed according to the target sequence, and in vitro transcription vectors pUC57-sgRNA1 and pUC57-sgRNA2 were constructed. After amplification and culture, plasmids were extracted and digested with DraⅠ and then recovered by gel. The recovered product was used as a template, and in vitro transcription was completed with T7 RNA polymerase. The product was purified by gel recovery, and finally the products sgRNA1 and sgRNA2 were concentrated to 200ng / μl by ethanol precipitation. sgRNA1, sgRNA2, Cas9 mRNA, and Donor vector were mixed evenly at a final concentration ratio of 200ng / μL: 200ng / μL: 200ng / μL: 200ng / μL.
[0049] (4) Preparation of fertilized eggs: Select 3-4 week old SD female mice and inject them with pregnant mare serum (PMSG) and human chorionic gonadotropin (hCG) respectively, with an interval of 46-48 hours between the two. After the injection of HCG, mate the female mice with adult fertile male mice to fertilize them. The next day, euthanize the female mice, collect the fertilized eggs from the fallopian tubes, and place them in a constant temperature incubator of 37°C and 5% CO2 for later use.
[0050] (5) Pronuclear microinjection: prepare microinjection needles and fixing needles; add the prepared mRNA injection solution to the microinjection needle; select fertilized eggs with normal morphology and place them in an injection dish. Under an inverted microscope with a magnification of 200 to 400 times, inject the exogenous gene injection solution into the nucleus of the fertilized egg by microinjection; transfer the injected fertilized eggs to M16 culture medium and place them in a constant temperature 37°C 5% CO2 incubator for 0.5 to 1 hour before transplantation.
[0051] (6) Preparation of surrogate mice and embryo transplantation
[0052] Prepare pseudo-pregnant female mice: select fertile female mice of appropriate age and mate with male mice that have been sterilized after vasectomy to stimulate a series of pregnancy changes in the female mice to obtain pseudo-pregnant female mice, which will serve as surrogate mice after the genetically modified fertilized eggs; transplant the fertilized eggs that have been injected with foreign genes into the fallopian tubes of surrogate female mice on the day of thrombus formation; after the transplantation, place the surrogate female mice in a clean cage and keep them warm until they wake up and then return them to the cage for breeding; after a successful fallopian tube transplantation, the female mice will generally give birth 19-20 days after the operation; one week after the mice are born, their claws can be clipped and numbered, and PCR identification can be performed at the same time; three weeks after the mice are born, they can be raised independently in separate cages.
[0053] (7) Identification of F0 mice
[0054] Collect tissues (tail or toe tissues) from 1- to 2-week-old young mice; lyse the tissues and extract genomes;
[0055] PCR amplification and electrophoresis detection are performed using specific primers for the target gene to screen out offspring with exogenous gene integration; mice with integration are called founder mice, which can be passaged and established, and the protein expression level can be identified if necessary. Among them, the specific primer sequences used for genotype identification of MARK2 gene mutant rats include Rat MARK2-F (5'-AAAGTGCCTGCCAGCCCTCT-3', SEQ ID NO:4) and Rat MARK2-R (5'-CAGTTTAGTGAGCTGCTCACTGGTAC-3', SEQ ID NO:5), the sequencing primer is sequence-F (5'-AGGGCGGAAAGCCAGCAGCA-3', SEQ ID NO:6), the PCR amplification system is shown in Table 1, and the amplification program is shown in Table 2. After amplification, the wild-type sequence is 605bp, and the mutant sequence is 604bp. The wild-type sequence is shown in SEQ ID NO:7, and the MARK2 mutant sequence is shown in SEQ ID NO:8 ( Figure 2 ).
[0056] Table 1 PCR amplification system
[0057] Reaction components Volume (μL) <![CDATA[ddH2O]]> 21.85 dNTP Mix 1.5 10×PCR buffer 3 HotStart Enzymes 0.15 Primer F 1 Primer R 1 DNA Template 1.5 Total 30
[0058] Table 2 PCR Amplification Program
[0059]
[0060] SEQ ID NO:7 (WT PCR product): 605bp
[0061] Aaagtgcctgccagccctctgcctggcctggacaggaagaagaccactcctaccccctccacagtaagccatgagctactccccccagccctggcctcctcctgtccactgatctcccttgctgaggcctggtcctcggctgtcccggagcttactgtagaaagtgggctgcagagcagcttgggacaagggcatccagtggtcctggggaagagcctgactggacagcactggctcctgtgacacagtacttgccctctatttcccacagaacagcgtcctctccaccagcacaaacagaagcaggaactccccacttttggacagggccagccttggccaggcctccatccagaatggtaaagacaggtgagtatctggactgaactacgtaccatgctcttggggttcacatctcacagtcggcagtgattcctgtcagtagcatcatcttctacctcgccagagcaatgtccctagagtcctgtcctggctctgttcagtctagccatctaccttccctccctgctccatgccatccctcctgtcttctgatccttgacatttgccaagcatagggtaccagtgagcagctcactaaactg;
[0062] SEQ ID NO:8 (Mutant PCR product): 604bp
[0063] aaagtgcctgccagccctctgcctggcctggacaggaagaagaccactcctaccccctccacagtaagccatgagctactccccccagccctggcctcctcctgtccactgatctcccttgctgaggcctggtcctcggctgtcccggagcttactgtagaaagtgggctgcag agcagcttgggacaagggcatccagtggtcctggggaagagcctgactggacagcactggctcctgtgacacagtacttgccctctatttcccacagaacagcgt-ctctccaccagcacaaacagaagcaggaactccccacttttggacagggccagccttggccaggcctc catccagaatggtaaagacaggtgagtatctggactgaactacgtaccatgctcttggggttcacatctcacagtcggcagtgattcctgt cagtagcatcatcttctacctcgccagagcaatgtccctagagtcctgtcctggctctgttcagtctagccatctaccttccctccctgctcc atgccatccctcctgtcttctgatccttgacatttgccaagcatagggtaccagtgagcagctcactaaactg;
[0064] (8) The positive F0 generation rats grown to 8 weeks old were mated with wild-type rats of the opposite sex to obtain F1 generation rats, and tail blood was collected for PCR amplification and identification (the detailed process is the same as step (3)) to obtain F1 generation heterozygous rats. The F1 generation heterozygous rats grown to 8 weeks old were further crossed to obtain F2 generation rats, and tail blood was collected for PCR amplification and identification (the same as above) to obtain positive F2 generation homozygous rats (KI / KI), which are MARK2 gene mutant rats (MARK2 mutant rats), and the MARK2 gene mutant rat autism animal model was constructed.
[0065] Effect Example
[0066] 1. The wild-type (WT) and MARK2 gene mutant homozygous rats (KI / KI) constructed in Example 1 were subjected to MARK2 protein expression detection. KI / KI rats expressed truncated MARK2 protein ( Figure 3 A) and the expression level was significantly decreased ( Figure 3B).
[0067] 2. One-month-old wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats from the same litter of F2 generation were selected for classic behavioral tests, including ultrasonic vocalization (USV), three-box social experiment, and grooming behavior test. It was found that the model mice had typical autism-like behaviors.
[0068] (1) Wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats from the same litter of F2 rats were subjected to ultrasonic vocalization detection at 0, 4, 7, 10, and 13 days after birth. It was found that the vocalization frequency and interval time of MARK2 mutant gene knock-in rats (KI / KI) were higher than those of wild-type (WT) and heterozygous (KI / +) rats ( Figure 4 A).
[0069] (2) One-month-old wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats from the same litter of F2 rats were subjected to a three-box social experiment. It was found that the social novelty of MARK2 gene mutation rats (KI / KI) was reduced ( Figure 4 C).
[0070] (3) One-month-old wild-type (WT), MARK2 gene mutation heterozygous (KI / +), and MARK2 gene mutation homozygous (KI / KI) rats from the same litter of F2 rats were subjected to grooming experiments. It was found that the grooming frequency of MARK2 gene mutation rats (KI / KI) was significantly higher than that of wild-type (WT) and heterozygous (KI / +) rats ( Figure 4 B) Demonstrates that this rat model has typical repetitive stereotyped behaviors.
[0071] In summary, this model can simulate the clinical phenotype of autistic patients more comprehensively. In summary, this model can be used to study the mechanism of autism caused by MARK2 gene mutation and may have great application value in the development of drugs for the treatment of autism.
[0072] The above specific implementations have been described in detail for the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A sgRNA, comprising sgRNA1 and / or sgRNA2, The sequence of the sgRNA1 is 5'-GTGGAGAGGACGCTGTTCTGTGG-3'; The sequence of the sgRNA2 is 5'-TCTGTTTGTGCTGGTGGAGAGG-3'.
2. A kit comprising the sgRNA according to claim 1.
3. The kit according to claim 2, characterized in that The kit also includes Cas9 mRNA and a homologous vector containing a mutation site, wherein the mutation site is c.1416delC.
4. The kit according to claim 3, characterized in that The nucleotide sequence of the homologous vector is: 5'-ACTGGACAGCACTGGCTCCTGTGACACAGTACTTGCCCTCTATTTCCCACAGAACAGCGTCTCTCCACCAGCACAAACAGAAGCAGGAACTCCCCACTTTTGGACAGGGCCAGCCTTGGCC-3'.
5. The kit according to claim 3, characterized in that The kit also includes amplification primers and / or sequencing primers; Preferably, the sequence of the amplification primer is: Rat MARK2-F: 5'-AAAGTGCCTGCCAGCCCTCT-3'; Rat MARK2-R: 5'-CAGTTTAGTGAGCTGCTCACTGGTAC-3'; Preferably, the sequence of the sequencing primer is: 5'-AGGGCGGAAAGCCAGCAGCA-3'.
6. Use of the sgRNA of claim 1 or the kit of any one of claims 2 to 5 in constructing an animal model of MARK2 gene mutation; preferably, the animal model is one of mouse, rat, and monkey; preferably, the animal model is rat.
7. A method for constructing an animal model of MARK2 gene mutation, the method comprising constructing the model by using the kit according to any one of claims 2 to 5.
8. The method according to claim 7, characterized in that The method specifically includes: introducing the mixture of the Cas9 mRNA, homologous vector, sgRNA1 and sgRNA2 into the fertilized eggs of the model animal, obtaining viable fertilized eggs, transplanting them into surrogate mothers, breeding, obtaining offspring and performing genotype identification and screening.
9. The method according to claim 8, characterized in that The mass ratio of the Cas9 mRNA, homologous vector, sgRNA1 and sgRNA2 in the mixture is 1:0.5-1.5:0.5-1.5:0.5-1.
5.
10. Use of the MARK2 gene mutation animal model constructed by the method according to any one of claims 7 to 9 in screening drugs for preventing and / or treating autism or studying the pathogenic mechanism of autism.
